Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
- L.C. Price*,#,¶,+,
- D. Montani*,#,¶,
- C. Tcherakian*,#,¶,
- P. Dorfmüller*,#,¶,
- R. Souza*,#,¶,
- N. Gambaryan*,#,¶,
- M-C. Chaumais*,#,¶,
- D.M. Shao+,
- G. Simonneau*,#,¶,
- L.S. Howard§,
- I.M. Adcockf,
- S.J. Wort+,
- M. Humbert*,#,¶⇑ and
- F. Perros*,#,¶
- *Faculté de Médecine, Université Paris-SudParis
- #AP-HP, Centre National de Référence de l'Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Clamart
- ¶INSERM U999, Hypertension Artérielle Pulmonaire, Physiopathologie et Innovation Thérapeutique, IPSIT, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France
- +Unit of Thoracic Critical Care
- fDept of Cell and Molecular Biology, Airways Disease Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London
- §National Pulmonary Hypertension Service, Dept of Cardiac Sciences, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
- M. Humbert, Centre National de Référence de l'Hypertension Artérielle Pulmonaire, Service de Pneumologie, Hôpital Antoine Béclère, Assistance Publique – Hôpitaux de Paris, Université Paris-Sud 11, 157 rue de la Porte de Trivaux, 92140 Clamart, France. E-mail: marc.humbert{at}abc.aphp.fr
Abstract
Pulmonary arterial hypertension (PAH) is associated with dysregulated bone morphogenetic protein receptor (BMPR)-II signaling and pulmonary vascular inflammation. We evaluated the effects of dexamethasone on monocrotaline (MCT)-induced PAH in rats for potential reversal of PAH at late time-points.
Saline-treated control, MCT-exposed, MCT-exposed and dexamethasone-treated rats (5 mg·kg−1·day−1, 1.25 mg·kg−1 and 2.5 mg·kg−1·48 h−1) were evaluated at day 28 and day 35 following MCT for haemodynamic parameters, right ventricular hypertrophy, morphometry, immunohistochemistry, and IL6 and BMPR2 expression.
Dexamethasone improved haemodynamics and pulmonary vascular remodelling, preventing PAH development at early (day 1–14 and 1–28) and reversing PAH at late (day 14–28 and 21–35) time-points following MCT, as well as improving survival in MCT-exposed rats compared with controls. Both MCT-induced pulmonary IL6 overexpression and interleukin (IL)-6-expressing adventitial inflammatory cell infiltration were reduced with dexamethasone. This was associated with pulmonary BMPR2 downregulation following MCT, which was increased with dexamethasone, in whole lung and control pulmonary artery smooth muscle cells. Dexamethasone also reduced proliferation of rat pulmonary artery smooth muscle cells in vitro.
Experimental PAH can be prevented and reversed by dexamethasone, and survival is improved. In this model, mechanisms may involve reduction of IL-6-expressing inflammatory cells, restoration of pulmonary BMPR2 expression and reduced proliferation of vascular smooth muscle cells.
- Bone morphogenetic protein receptor
- corticosteroids
- inflammation
- monocrotaline
- pulmonary arterial hypertension
- type II
Pulmonary arterial hypertension (PAH) is characterised by a progressive increase in pulmonary vascular resistance, ultimately leading to right ventricular failure and death 1. The principal pathological finding is remodelling of small pulmonary arteries with marked proliferation of pulmonary artery smooth muscle cells (PASMC), resulting in obstruction of these resistance pulmonary arteries 2. Inflammatory mechanisms are believed to play a key role in both human and experimental PAH 3. In idiopathic (I)PAH, infiltrates of macrophages and lymphocytes are found in the range of plexiform lesions with local expression of chemokines CC motif ligand (CCL)2 (monocyte chemotactic protein-1), CCL5 (RANTES (regulated on activation, normal T-cell expressed and secreted)) and CX3C motif ligand 1 (fractalkine) 4–7. Histopathological specimens from patients displaying severe PAH in the context of connective tissue diseases suggest that inflammation and remodelling are key contributors to pulmonary vascular disease complicating inflammatory diseases 4. Proinflammatory cytokines, including interleukin (IL)-1 and IL-6, are elevated in both human IPAH 8 and MCT-induced PAH 9, 10. Autoimmunity is also demonstrated to contribute to PAH in patients characterised by circulating autoantibodies 11. Pathogenic autoantibodies target endothelial cells and may induce vascular endothelial apoptosis, promoting PAH development 12.
The suggestion that treatment with corticosteroids and/or immunosuppressants may dramatically improve PAH stems from the improvement seen in associated PAH following treatment for coexisting systemic inflammatory conditions, including POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal immunoglobulin and skin changes) syndrome 13, Castleman's disease 14, systemic lupus erythematosus (SLE) 15, 16 and mixed connective tissue disease 15, 16. Immunosuppressive therapies including rapamycin 17 and cyclosporin 18 have been shown to attenuate the development of PAH in rats exposed to MCT, including established PAH 17, 18. Earlier studies have shown that steroids prevent the development of MCT-induced PAH 9, 19–21, although no studies have yet shown that steroids reverse established MCT-induced PAH.
Mutations in the bone morphogenetic protein receptor (BMPR)-II gene (BMPR2) have been identified in >50% of familial (F)PAH patients and 10–25% of IPAH patients 22, 23. Reduced levels of BMPR1a 24 and BMPR2 25, 26 mRNA expression are seen in the lungs of patients with heritable PAH and IPAH, and in other subtypes of PAH. This reduction in pulmonary BMPR2 is mirrored in MCT-induced PAH 27, 28. These mutations disrupt bone morphogenetic protein (BMP)/Smad-mediated signalling 29, potentiate BMP/mitogen-activated protein kinase signalling 30 and could underlie the abnormal vascular cell proliferation observed in FPAH 31. Interestingly, several studies suggest that dysregulation of the BMP pathway leads to vulnerability to an inflammatory second hit 32–34.
The aim of this study was to test the effects of dexamethasone on pulmonary haemodynamics, and IL6 and BMPR2 expression in the asymptomatic and symptomatic phases of development of MCT-induced PAH in rats. We hypothesised that dexamethasone treatment could reverse haemodynamics in established MCT-induced PAH, and that haemodynamic improvements would correlate with normalisation of IL6 and BMPR2 mRNA levels.
METHODS
Study design
Male Wistar rats (100 g body weight) were maintained in a temperature-controlled room with a 12/12-h light/dark cycle and randomly divided into: 1) a saline-treated control group (n = 20); 2) an MCT-exposed group (n = 20); 3) an MCT-exposed and 5 mg·kg−1·day−1 (day 1–14) dexamethasone-treated group (MCT+Dex D1–14; n = 20); 4) an MCT-exposed and 5 mg·kg−1·day−1 (i.p.; day 1–28) dexamethasone-treated group (MCT+Dex D1–28; n = 10); 5) an MCT-exposed and dexamethasone-treated (three dose ranges of 5 mg·kg−1·day−1 (Dex5), 2.5 mg·kg−1·48 h−1 (Dex2.5) and 1.25 mg·kg−1·48 h−1 (Dex1.25); day 14–28; MCT+Dex D14–28) (n = 10 per group); and 6) an MCT-exposed and 5 mg·kg−1·day−1 (day 21–35) dexamethasone-treated group (MCT+Dex D21–35) (n = 10 per group). All rats had access to standard rat chow and water ad libitum. For MCT administration, rats received a single subcutaneous injection of 60 mg·kg−1 MCT (Sigma–Aldrich, Lyon, France), which was dissolved in 1 N HCl, and the pH was adjusted to 7.4 with 1 N NaOH. Ten rats from groups 1–3 were sacrificed to perform experiments 14 days after the MCT exposure and the remaining 10 rats from each group were then sacrificed at 28 or 35 days after MCT exposure.
Haemodynamics
As described by Stinger et al. 35, a 3.5 French umbilical vessel catheter (Tyco, Plaisir, France), angled to 90° over the distal 1 cm and curved slightly at the tip, was introduced into the right external jugular vein of rats anaesthetised with 35 mg·kg−1 ketamine, 4 mg·kg−1 xylasine and 0.5 mg·kg−1 acepromazine. Following deaths during anaesthesia in preliminary experiments, presumed relative adrenal suppression was managed using a 5 mg·kg−1 dose of i.p. dexamethasone prior to induction of anaesthesia. With the angle directed anteriorly, the catheter was inserted 2.5 cm proximally, which placed the catheter in the right atrium. The catheter was rotated 90° anticlockwise and inserted 1 cm further, which placed the catheter in the right ventricle, and when advanced an additional 1.5 cm, in the pulmonary artery. Placement at each stage was confirmed by respective pressure contours. Haemodynamic values were automatically calculated by the physiological data acquisition system Cardiomax III (Phymep, Paris, France). Following exsanguination, the lungs were distended by infusion of Optimal Cutting Temperature compound (Miles, Epernon, France) diluted in PBS (1:1) into the trachea, quick-frozen in isopentane on dry ice and stored at -80°C. For Fulton's index of right ventricular hypertrophy, the ratio of the right ventricular weight to left ventricular plus septal weight (RV/LV+S) was calculated.
Gene quantification by quantitative real-time RT-PCR
RNA was extracted from rat lungs using the Total RNA Isolation Mini Kit (Agilent Technologies, Massy, France) and then eluted from silicate columns and reverse-transcribed using the Omniscript Reverse Transcription Kit (Qiagen, Courtaboeuf, France). Constitutively expressed β-actin was selected as an internal housekeeping gene control for the comparative CT method for the relative quantification of BMPR2 and IL6 mRNA expression. BMPR2, IL6 and β-actin expression was quantified by RT-PCR using TaqMan Gene Expression Assays (β-actin Rn00667869_m1, BMPR2 Rn01437210_m1 and IL6 Rn00561420_m1), TaqMan Universal PCR Master Mix and an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Courtaboeuf, France).
Immunohistochemistry
Immunohistochemistry was performed on 8-μm sections of frozen tissue (-80°C). After routine preparation, slides were processed with the primary antibody anti-IL-6 (1:600; Abcam rabbit polyclonal ab6672; Abcam, Cambridge, UK), then with the secondary antibody (anti-rabbit; kit En Vision+/HRP; Dako, Trappes, France). Controls used for these antibodies included omission of the primary antibody and incubation with irrelevant immunoglobulins of the same isotype.
Pulmonary artery morphometry
Sections of paraffin-embedded lungs were prepared and stained with haematoxylin and eosin. The slides were evaluated by light microscopy, and the extent of vascular remodelling was assessed by a researcher blinded to the treatment groups. Three whole left lung sections from each rat were evaluated. The percentage medial wall (media/external diameter (ED)×100) and adventitial thickness (adventitia/ED×100) of fully muscularised, pre-acinar pulmonary arteries was measured, using 10 randomly chosen vessels from each of the three sections for each rat. For arterioles (<80 μm ED), the degree of muscularisation was score of a scale of 1–3, where: 1 = no muscularisation, not occluded; 2 = muscularisation, not occluded; and 3 = muscularisation, fully occluded).
Primary smooth muscle cell isolation and culture
At baseline (control) and 21 days following exposure to MCT, rats were sacrificed using an overdose of pentobarbital. The lungs were immediately removed and proximal pulmonary arteries were isolated. PASMCs were isolated by enzymatic digestion 36, with purity and verification of PASMCs using immunostaining for smooth muscle α-actin as previously described 37.
Measurement of PASMC proliferation
PASMCs were cultured to 80% confluence in passage 3–6. On day 0 of the proliferation assay, cells were detached with 0.05% trypsin and 0.02% EDTA and seeded in 48-well plates at a density of 5×104 cells·well−1 (in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS)). After 48 h of incubation (day 2), the cells were serum-starved (in DMEM with 0.1% FCS) for 24 h. On day 3, cells were washed twice with PBS and recultured in DMEM (10% FCS) with dexamethasone (Sigma–Aldrich). On the basis of preliminary experiments examining the antiproliferative effects of dexamethasone on 10% FCS-stimulated rat PASMCs, the final concentrations used were 10−7–10−8 M. Controls were cultured in DMEM with 10% FCS. On day 4, 24 h after the addition of dexamethasone, the cells were labelled with 3H-thymidine at 1 μCi·mL−1 for 24 h and frozen at -80°C. After labelling was completed in all samples, the cells were washed in situ with 500 μL ice-cold uptake buffer, lysed with 500 μL of 0.1 N NaOH and the radioactivity counted using liquid scintillation spectroscopy 37.
Statistical analysis
Data are presented as mean±sem, unless otherwise stated. Data were analysed using the nonparametric Kruskal–Wallis test followed by Dunn's test for multiple comparisons, the Mann–Whitney U-test and Spearman's rank correlation. Differences were considered significant at p-values <0.05. Analyses were performed using Statview 5.0.
RESULTS
Dexamethasone treatment improves survival in established MCT-induced PAH
Treatment with 5 mg·kg−1·day−1 dexamethasone from day 14–28 significantly improved survival assessed at day 28 compared with MCT alone (log rank test p<0.0001; fig. 1). Survival was also significantly improved at day 35 following day 21–35 dexamethasone (data not shown).
Dexamethasone treatment normalises haemodynamics and right ventricular hypertrophy in established MCT-induced PAH
28 days after MCT administration, haemodynamic measurements showed a significant increase in mean pulmonary arterial pressure (P̄pa; 40.8±6.4 versus 16.4±1.5 mmHg in control animals; p<0.0001; fig. 2a), right ventricular systolic pressure (RVSP; 94.3±7.8 versus 35.2±2.4 mmHg in control rats; p<0.0001; fig. 2b) and RV/LV+S (0.6±0.1 versus 0.26±0.06 in controls; p<0.0001; fig. 2c). MCT+Dex D14–28 administration normalised the P̄pa (p<0.05 for Dex5 and Dex2.5; p = 0.066 for Dex1.25), RVSP (p<0.0001 for Dex5 and Dex2.5, and p<0.05 for Dex1.25) and RV/LV+S (p<0.0001 for all doses) in a dose-dependent manner. Dex5 was not statistically different to control rats (p = 0.11). MCT+Dex D21–35 also normalised P̄pa, RVSP and RV/LV+S (p<0.05 for all compared to MCT alone; fig. 3). Haemodynamic indices were also normalised in all earlier, preventative-phase dexamethasone-treated groups (MCT+Dex D1–14 and D1–28; p<0.001 for both; data not shown).
Dexamethasone treatment reverses pulmonary vascular remodelling in established MCT-induced PAH
Dexamethasone treatment (day 14–28) reduced the degree of muscularisation of peripheral pulmonary arteries and arterioles, as assessed by morphometric analysis. MCT significantly increased the percentage medial thickness of pre-acinar pulmonary arteries (expressed as media/ED×100) at day 28 compared to controls (31.4±10.1 versus 10.8±4.93%; p<0.0001). This was reduced in a dose-dependent fashion in all the MCT+Dex D14–28 group at day 28 compared to MCT alone (20.7±9.47%, 18.8±7.7% and 14.7±7.46% for Dex1.25, Dex2.5 and Dex5, respectively, versus 31.4±10.1%; p<0.0001 for all). Pulmonary arterial adventitial thickness was also increased at day 28 following MCT compared with control rats (36.5±34.3 versus 8.83±4.95%; p<0.0001), which was reduced with all D14–28 dexamethasone doses (24.0±12.6%, 16.3±10.4% and 9.47±5.39 for Dex1.25, Dex2.5 and Dex5, respectively, versus 36.5±34.3%; p<0.0001 for Dex5 and Dex2.5, and p<0.05 for Dex1.25; fig. 4a and b). At day 28 following MCT, there was a significant increase in pulmonary arteriolar (i.e. vessels <80 μm ED) muscularisation, with an increase seen in the percentage of both nonoccluded and occluded arterioles compared with control rats (p<0.0001). Following MCT+Dex D14–28, the arteriolar muscularisation score was reduced in a dose–dependent manner (p<0.05 for all groups; fig. 4c).
Dexamethasone reduces MCT-induced adventitial infiltration of IL-6-expressing inflammatory cells
In control lungs, immunohistochemistry showed only a weak staining of IL-6 in control lungs (fig. 5a), whereas 28 days after MCT administration, adventitial infiltrating inflammatory cells displayed a strong IL-6 expression in MCT-exposed rats (fig. 5b). Lungs from the MCT+Dex D1–28 group exhibited the same faint IL-6 staining as seen in control lungs (fig. 5c).
Dexamethasone inhibits MCT-induced pulmonary IL-6 overexpression
28 days after MCT administration, pulmonary IL6 mRNA expression measured by quantiative RT-PCR was strongly increased (p<0.01). MCT+Dex D1–28 normalised whole-lung IL6 mRNA expression (p<0.05 versus MCT-exposed lungs; no significant difference seen with control lungs). Furthermore, IL6 was reduced by late (MCT+Dex D14–28) dexamethasone treatment, (p<0.05 versus MCT-exposed lungs at day28) (fig. 6).
Dexamethasone increases pulmonary BMPR2 downregulation in MCT-induced PAH
28 days after MCT administration, pulmonary BMPR2 mRNA expression was strongly downregulated (p<0.01). MCT+Dex D1–28 (fig. 7a) and D14–28 (fig. 7b) increased whole-lung BMPR2 expression (p<0.01 and p<0.05 for MCT+Dex D1–28 and D14–28, respectively, versus MCT-exposed lungs; not significantly different to control lungs).
Dexamethasone inhibits proliferation of cultured rat PASMC
Proliferation of PASMC isolated from pulmonary hypertensive rats (at day 21 following MCT), as assessed by 3H-thymidine uptake, was inhibited following dexamethasone treatment in a dose-dependent manner, compared with controls in complete medium without dexamethasone (38% reduction at 10−8 M dexamethasone and 88% reduction at 10−7 M dexamethasone; p<0.05 for both doses compared to controls). Similar results were obtained using manual cell counting techniques (data not shown). At 10−8 M dexamethasone, cells isolated from control rats were growth-inhibited to a greater extent by dexamethasone compared with PASMCs from MCT-exposed rats (p<0.05) (fig. 8).
Dexamethasone increases BMPR2 and reduces IL-6 expression in rat PASMCs
Treatment of rat PASMCs with 10−8 M dexamethasone led to an increase in cellular BMPR2, as measured by quantitative RT-PCR in control cells (p<0.05 compared with untreated cells), whereas there was no significant difference in BMPR2 following dexamethasone treatment in cells isolated from pulmonary hypertensive rats (fig. 9a). IL6 mRNA was reduced following dexamethasone treatment (p<0.05 for both control and MCT-exposed cells; fig. 9b).
DISCUSSION
The major findings of this study were as follows. 1) Dexamethasone improved survival in rats with established MCT-induced PAH, with normalisation of haemodynamics, right ventricular hypertrophy and pulmonary vascular remodelling at late time points after MCT. 2) Consistent with previous findings, MCT downregulated BMPR2 expression and increased IL-6 activity: we showed that haemodynamic improvements with dexamethasone treatment were associated with a normalization of BMPR2. 3) Reduced pulmonary IL6 overexpression and a reduction in the adventitial infiltration of IL-6-expressing inflammatory cells. 4) Dexamethasone inhibited rat PASMC proliferation, which was associated with a reduction in IL6 expression and an increase of BMPR2 in control PASMCs. 5) PASMCs isolated from pulmonary hypertensive rats appeared relatively resistant to the BMPR2 mRNA increase and the anti-proliferative effects of dexamethasone.
Monocrotaline is an “inflammatory” model of PAH, comprising an initial asymptomatic inflammatory phase, followed by a less inflammatory symptomatic phase from day 14, with increased medial volume in both major and intra-acinar pulmonary arteries by 21 days exposure 38, 39. Previous studies have similarly shown that preventive immunosuppressive therapy is effective in MCT-induced PAH when given before the onset of pulmonary vascular remodelling (i.e. prior to day 14) 9, 17, 18, 40–43. However, although there have been some studies showing reversal of PAH at later time-points with various anti-inflammatory therapies, none has yet used glucocorticoids. The reversal of MCT-induced PAH beyond the onset of vascular remodelling is of clinical relevance. Although patients with IPAH are not believed to have steroid-responsive disease, clinical improvement of PAH is seen in associated inflammatory conditions where immunosuppression (including glucocorticoids) was otherwise indicated, including PAH associated with connective tissue diseases 44 and SLE 45. Interestingly, this improvement in PAH occurs particularly in those with earlier, less severe PAH 16, perhaps suggesting that immunosuppressive therapies may be more effective in proliferating, active lesions in early disease than in those with established, fixed pulmonary vascular lesions.
Among the wide spectrum of biological actions of glucocorticoids, dexamethasone has been shown to inhibit vascular cell proliferation 46. The antiproliferative findings in this study are consistent with a study of prednisolone on platelet-derived growth factor-stimulated PASMCs from PAH patients 47, although that study used much higher doses (equating to 3×10−5 and 3×10−4 M dexamethasone).
Mutations in BMPR2 have been shown to be important in familial IPAH 22. BMPs are members of the transforming growth factor (TGF)-β superfamily, which, through type 1 and 2 receptors, contribute to regulation of cell proliferation, differentiation and apoptosis. In humans, a variety of cell types, including PASMCs and endothelial 48 cells, synthesise and secrete BMPs. BMPR-II-positive cells have also been shown to be closely associated with the inflammatory cell infiltrate in IPAH lesions 49. One of the normal roles of the BMP signalling pathway is believed to be the prevention of runaway positive feedback loops in inflammatory cytokines. Reduced expression of BMPR-II has been reported in most types of human PAH and an attractive theory is that the dysregulated BMPR-II signalling is followed by an inflammatory second hit early in the pathogenesis of PAH. Our data are consistent with previous studies 27, 28 showing a reduction in BMPR-II in MCT-induced PAH in rats and, as far as we are aware, this is the first study to show a glucocorticoid-induced increase in the low BMPR2 levels in MCT-induced PAH. The importance of IL-6 has been shown in several studies of PAH. Patients with PAH have increased circulating IL-6 levels 8 and IL-6 is capable, on its own, of causing growth of vascular smooth muscle cells 50 and PAH 51. In transgenic mice, IL-6 overexpression induces PAH associated with downregulation of TGF-β signalling 52. Consistent with previous studies 9, 51, we found that MCT-induced PAH is also associated with increased IL-6 production. Kaposi's sarcoma-associated herpes virus, which may cause PAH in HIV-negative Castleman's disease, encodes a viral, constitutively active form of IL-6 53. In addition, recent studies have suggested the involvement of viral infection or autoimmunity 12 in the development of PAH. Thus, there is substantial evidence that the unknown second hit is likely to be inflammatory in character. Hagen et al. 34 have identified a negative feedback loop between IL-6 and the BMP pathway, in which increased IL-6 induces BMP pathway activity and increased BMP pathway activity suppresses IL-6. Furthermore, IL-6 enhances proliferation via activation of signal transducer and activator of transcription 3 54, persistent activation of which has been shown to reduce BMPR-II expression, which may contribute to the loss of BMPR-II during PAH development 55. Further work showing that, although asymptomatic BMPR2+/- mice do not develop pulmonary hypertension spontaneously, under inflammatory stress, they are more susceptible than wild-type mice 32 and mice expressing a dominant-negative BMPR2 allele in smooth muscle develop elevated right ventricular pressures, with an increase in cytokines and markers of immune response, when the transgene is activated 33. BMPR-II dysfunction and resulting loss of activity may, therefore, result in unopposed IL-6 production in the context of an as yet unknown inflammatory stimulus.
Our data suggest that dexamethasone interrupts the IL-6–BMPR-II negative feedback loop 34, probably mainly through a dexamethasone-induced reduction in IL-6-expressing inflammatory cells and, possibly, also a direct PASMC effect. The resulting increase in pulmonary BMPR2 mRNA may thus restore the required dampening effects of BMPR-II signalling on IL-6 function. The mechanisms through which glucocorticoids interact with BMPR-II are unclear, but a gene expression profiling study of asthmatics receiving glucocorticoids suggests an important interaction between the sensitivity of the glucocorticoid receptor and BMPR-II 56.
Limitations of our study include the absence of BMPR-II protein expression analysis to confirm the findings in gene transcription assays, the lack of immunohistochemistry for BMPR-II and the lack of IL-6 immunohistochemistry at later treatment time-points, although we replaced this with quantitative data using RT-PCR for IL6 and BMPR2 at these time-points.
In conclusion, we have shown that treatment with dexamethasone improves haemodynamics, reduces remodelling and improves survival in established MCT-induced PAH, with normalisation of BMPR2 expression and inflammatory responses. These findings provide new insight into the potential role of immunosuppressants in the treatment of human PAH via the regulation of the BMPR-II and IL-6 pathways.
Footnotes
Support Statement
The study was supported by Chancellerie des Hoˆpitaux de Paris (Legs Poix), Universite´ Paris-Sud 11 and Ministre`re de l’Enseignement Supe´rieur et de la Recherche. A European Respiratory Society longterm research fellowship was awarded to L.C. Price (no. 139).
Statement of Interest
Statements of interest for D. Montani, R. Souza, G. Simonneau and M. Humbert can be found at www.erj.ersjournals.com/site/misc/statements.xhtml
- Received February 20, 2010.
- Accepted July 15, 2010.
- ©2011 ERS